SLC5A2 and Hypoglycemia: SGLT2 inhibitors were associated with a similar risk of hypoglycemia as a placebo [risk ratio 1.16 (95% CI 0.93–1.45), p = 0.20], and the IPRA group showed a significant difference in the sub-group analysis.